PL408347A1 - Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P - Google Patents

Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P

Info

Publication number
PL408347A1
PL408347A1 PL408347A PL40834703A PL408347A1 PL 408347 A1 PL408347 A1 PL 408347A1 PL 408347 A PL408347 A PL 408347A PL 40834703 A PL40834703 A PL 40834703A PL 408347 A1 PL408347 A1 PL 408347A1
Authority
PL
Poland
Prior art keywords
inhibitors
combination
antagonists
expression
receptor agonist
Prior art date
Application number
PL408347A
Other languages
English (en)
Inventor
Carolyn Ann Foster
Peter C. Hiestand
Paul William Glue
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL408347A1 publication Critical patent/PL408347A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Wynalazek dotyczy kombinacji zawierającej pierwszy składnik czynny wybrany spośród 2-amino-2-[2-(4-oktylofenylo)etylo]propano-1,3-diol, w postaci wolnej albo w postaci farmaceutycznie dopuszczalnej soli oraz fosforanu-FTY720, oraz składnik towarzyszący wybrany z grupy składającej się z interferonów, zmodyfikowanych ligandów peptydowych, immunosupresantów, inhibitorów deaminazy adenozynowej, inhibitorów mTOR, immunoglobuliny G IV, przeciwciał monoklonalnych przeciwko znacznikom powierzchniowym limfocytów T, cytokin promujących TH2, związków, które hamują ekspresję cytokin promujących TH1, środków przeciwspastycznych, antagonistów receptora glutaminianowego AMPA, inhibitorów katepsyny S, inhibitorów ekspresji VCAM-1 lub antagonistów jego ligandu oraz przeciwciał przeciwko czynnikowi hamującemu migrację makrofagów oraz zastosowania takiej kombinacji. Wynalazek dotyczy również zastosowania agonisty receptora S1P.
PL408347A 2002-09-24 2003-09-23 Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P PL408347A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317202P 2002-09-24 2002-09-24
US48513203P 2003-07-07 2003-07-07

Publications (1)

Publication Number Publication Date
PL408347A1 true PL408347A1 (pl) 2014-08-18

Family

ID=32045240

Family Applications (2)

Application Number Title Priority Date Filing Date
PL408347A PL408347A1 (pl) 2002-09-24 2003-09-23 Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P
PL03375053A PL375053A1 (pl) 2002-09-24 2003-09-23 Agoniści receptora sfingozyno-1-fosforanu w leczeniu zaburzeń demielinizacyjnych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL03375053A PL375053A1 (pl) 2002-09-24 2003-09-23 Agoniści receptora sfingozyno-1-fosforanu w leczeniu zaburzeń demielinizacyjnych

Country Status (16)

Country Link
US (4) US20060046979A1 (pl)
EP (3) EP1575576A2 (pl)
JP (2) JP4509028B2 (pl)
KR (4) KR101095807B1 (pl)
CN (3) CN1708293A (pl)
AU (3) AU2003266404B2 (pl)
BR (1) BR0314760A (pl)
CA (1) CA2499622C (pl)
MX (1) MXPA05003254A (pl)
NO (2) NO334908B1 (pl)
NZ (2) NZ564626A (pl)
PL (2) PL408347A1 (pl)
RU (3) RU2391094C2 (pl)
TW (2) TWI376363B (pl)
WO (1) WO2004028521A2 (pl)
ZA (1) ZA200502032B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010688A1 (it) 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
RU2330839C2 (ru) 2002-01-11 2008-08-10 Санкио Компани, Лимитед Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
WO2003094965A2 (en) 2002-05-08 2003-11-20 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
US7241790B2 (en) 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
US20050090520A1 (en) * 2003-09-12 2005-04-28 Per Lindquist Treatment of disease or injury of the nervous system with FTY720
WO2005041899A2 (en) 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
JP2007513972A (ja) * 2003-12-11 2007-05-31 アクシス・ファーマシューティカルズ・インコーポレイテッド 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンｓインヒビターの使用
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
TWI355934B (en) 2004-02-24 2012-01-11 Sankyo Co Pharmaceutical composition for treatment or prophy
MXPA06012663A (es) * 2004-05-03 2007-01-16 Novartis Ag Combinaciones que comprenden un agonista del receptor s1p y un inhibidor de quinasa jak3.
ATE502630T1 (de) 2004-07-16 2011-04-15 Kyorin Seiyaku Kk Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen
AU2005292984B2 (en) * 2004-10-12 2011-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrate thereof and intermediate for the same
EP1650186B1 (en) * 2004-10-22 2008-06-04 Bioprojet Novel dicarboxylic acid derivatives
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
JP2008522977A (ja) 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
RS52193B (sr) 2004-12-21 2012-10-31 Merck Serono Sa. Ciklični derivati sulfonil amina i njihova upotreba
UA86862C2 (en) 2005-01-31 2009-05-25 Лаборатуар Сероно С.А. N-hydroxyamide derivatives and use thereof
MX2007009848A (es) 2005-02-14 2008-03-10 Univ Virginia Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo.
GB0513431D0 (en) 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
JP2009507003A (ja) * 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
NZ588372A (en) * 2005-09-09 2012-03-30 Novartis Ag Diphenyl ether or thioether derivatives for treatment of autoimmune diseases
RU2421214C2 (ru) * 2005-10-07 2011-06-20 Киорин Фармасьютикал Ко., Лтд. Терапевтическое средство для лечения гепатита и способ лечения гепатита
WO2007078726A2 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
MX2008009579A (es) 2006-01-27 2008-09-25 Univ Virginia Metodo para el tratamiento de dolor neuropatico.
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2007212193A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
US8232319B2 (en) * 2006-08-08 2012-07-31 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and S1P receptor modulator having same as an active ingredient
AU2012216651B2 (en) * 2006-08-17 2013-08-01 University Of Chicago Treatment of inflammatory diseases
WO2008021532A2 (en) * 2006-08-17 2008-02-21 University Of Chicago Treatment of inflammatory diseases
EP2099741A2 (en) 2006-11-21 2009-09-16 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
WO2008064337A2 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
AU2007323618A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
EP2305305A4 (en) * 2008-05-20 2013-02-13 Kyorin Seiyaku Kk MEDIUM FOR INTRODUCTION / MAINTENANCE OF THE REMISSION
KR20180017232A (ko) * 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
CA2734585A1 (en) * 2008-08-18 2010-02-25 Novartis Ag Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
US10022340B2 (en) 2013-10-11 2018-07-17 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
CN103992985A (zh) * 2014-05-09 2014-08-20 上海大学 神经鞘氨醇在中枢神经系统中的作用
ES2769902B2 (es) * 2018-12-28 2020-12-04 Consejo Superior Investigacion Uso de secoiridoides para el tratamiento de la neuritis óptica.
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
TW202131914A (zh) 2019-10-30 2021-09-01 西班牙商布爾奴爾法碼有限公司 用於神經疾病或病狀的治療之新治療方案

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654333A (en) * 1986-02-18 1987-03-31 Unimed, Inc. Treatment of multiple sclerosis
RU2079304C1 (ru) * 1990-11-08 1997-05-20 Фудзисава Фармасьютикал Ко., Лтд. Фармацевтическая композиция, обладающая иммуносупрессорной и антимикробной активностями
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
PT734389E (pt) 1993-12-17 2000-09-29 Novartis Ag Derivados de rapamicina uteis como imunossupressores
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
JP3870419B2 (ja) 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
CA2286315C (en) * 1997-04-04 2007-03-06 Yoshitomi Pharmaceutical Industries Ltd. 2-aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
DE19739693A1 (de) * 1997-09-04 1999-03-11 Schering Ag Pharmazeutische Präparate zur Behandlung der Multiplen Sklerose
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
JP2002537293A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンｌおよび／またはカテプシンｓの阻害剤としてのアセタミドアセトニトリル誘導体
JP2002537294A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンｌ及びカテプシンｓの阻害剤としてのジ−及びトリペプチドニトリル誘導体
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
AU7490900A (en) 1999-09-16 2001-04-17 Axys Pharmaceuticals, Inc. Chemical compounds and compositions and their use as cathepsin s inhibitors
CO5280088A1 (es) 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
NZ533997A (en) 2000-07-13 2005-11-25 Sankyo Co Amino alcohol derivatives
JP2002289768A (ja) * 2000-07-17 2002-10-04 Rohm Co Ltd 半導体装置およびその製法
AU2001281255B2 (en) 2000-08-14 2006-07-20 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
PT1309592E (pt) 2000-08-14 2006-07-31 Ortho Mcneil Pharm Inc Pirazoles substituidos
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
WO2002032879A1 (en) 2000-10-19 2002-04-25 Naeja Pharmaceutical Inc. Dihydropyrimidine derivatives as cysteine protease inhibitors
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
US7326801B2 (en) 2001-03-26 2008-02-05 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
RS19504A (sr) 2001-09-14 2007-02-05 Aventis Pharmaceuticals Inc., Nova jedinjenja i kompozicije kao inhibitori katepsina
WO2003024923A1 (en) 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
ATE463478T1 (de) * 2001-09-27 2010-04-15 Kyorin Seiyaku Kk Diaryletherderivat, dessen additionssalz und immunosuppressivum
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
EP1434769A2 (en) 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
JP2005508979A (ja) 2001-10-29 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆性インヒビターとして有用な化合物
DE60225316T2 (de) 2001-11-13 2009-02-26 AXYS Pharmaceuticals, Inc., South San Francisco Cyanoalkylamino-derivate als protease-hemmer
HUP0401906A3 (en) 2001-11-14 2008-07-28 Aventis Pharma Inc Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP4509028B2 (ja) 2010-07-21
RU2012153692A (ru) 2014-06-20
NO334908B1 (no) 2014-07-07
KR101095807B1 (ko) 2011-12-21
AU2003266404B2 (en) 2007-08-09
NZ564626A (en) 2009-08-28
NZ538961A (en) 2008-02-29
KR20050054958A (ko) 2005-06-10
ZA200502032B (en) 2005-10-26
AU2003266404A1 (en) 2004-04-19
EP2251007A3 (en) 2011-03-23
WO2004028521A3 (en) 2004-05-27
EP1575576A2 (en) 2005-09-21
US20060046979A1 (en) 2006-03-02
TW201100359A (en) 2011-01-01
US20090324542A1 (en) 2009-12-31
CN102526079B (zh) 2014-06-18
RU2478378C2 (ru) 2013-04-10
EP2255798A2 (en) 2010-12-01
RU2391094C2 (ru) 2010-06-10
KR20090125226A (ko) 2009-12-03
US20140271541A1 (en) 2014-09-18
CN101843897A (zh) 2010-09-29
TWI376363B (en) 2012-11-11
EP2255798B1 (en) 2014-12-24
TWI335311B (en) 2011-01-01
CN102526079A (zh) 2012-07-04
RU2009136626A (ru) 2011-04-10
KR101188943B1 (ko) 2012-10-08
MXPA05003254A (es) 2005-06-08
AU2010246492A1 (en) 2010-12-23
PL375053A1 (pl) 2005-11-14
BR0314760A (pt) 2005-07-26
CA2499622C (en) 2012-01-03
JP2006503924A (ja) 2006-02-02
WO2004028521A2 (en) 2004-04-08
CN1708293A (zh) 2005-12-14
US20120225031A1 (en) 2012-09-06
EP2255798A3 (en) 2011-03-23
CN101843897B (zh) 2014-04-30
KR20110038188A (ko) 2011-04-13
AU2007231645A1 (en) 2007-11-15
CA2499622A1 (en) 2004-04-08
TW200406369A (en) 2004-05-01
NO20051934L (no) 2005-04-20
KR20080103117A (ko) 2008-11-26
EP2251007A2 (en) 2010-11-17
JP2010120962A (ja) 2010-06-03
RU2005112714A (ru) 2006-01-27
NO20131569L (no) 2005-04-20
AU2007231645B2 (en) 2010-12-16
AU2010246492B2 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
RU2005112714A (ru) Органические соединения
PL402389A1 (pl) Sposób hamowania aktywnosci kinazy Raf u ludzi lub zwierzat
EA200501586A1 (ru) Фармацевтические продукты
CR6687A (es) Composiciones farmaceuticas que comprenden inhibidoras de la hmg coa reductasa
DK1666481T3 (da) 3-((3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidinyl)-3-oxo-propionitril som proteinkinase inhibitor
RU2006116896A (ru) Терапевтический агент для мезотелиомы
NO20060667L (no) Ikke beroligende alfa-2-agonister 1-(2,3-dimetyl- fenyl)-etyl-1,3-dihydro-imidazol-2-tion
CY1119536T1 (el) Συνθεση μονομερων προστατευμενου 3'-αμινο νουκλεοζιδιου
ATE530577T1 (de) Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
DE60335807D1 (de) Amphetaminsalz-formulierung mit verzögerter wirkstofffreigabe
BR0206492A (pt) Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células
CA2483594A1 (en) Use of edg receptor binding agents in cancer
JP2005513021A5 (pl)
ATE350060T1 (de) Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
FR2838739B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
BR9710704A (pt) Uso de inibidores de proteina cinase c para aumentar a efic cia cl¡nica de agentes oncol¡ticos e terapia de radia-Æo
DE60302157D1 (de) Opioidrezeptorantagonisten
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
EA201170250A1 (ru) Терапевтическое средство от мигрени
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
BR0015980A (pt) Agente para profilaxia ou tratamento do glaucoma, e, uso de um antagonista de angiotensina ii
CA2446828A1 (en) Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
MX2022015003A (es) Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
EA200600675A1 (ru) Гранулы, содержащие гидрохлорид венлафаксина
EA200401628A1 (ru) Ингибиторы пептидной деформилазы